Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Dietary Supplement Action; AI in Healthcare; Border Crossings for Medicine
February 12, 2019 – AJMC Staff
Top 5 AJMC® Articles of January 2019
January 31, 2019
FDA Approves Sumatriptan Nasal Spray for Acute Migraine
January 30, 2019 – Jaime Rosenberg
What We're Reading: Contaminated Blood Pressure Drugs; Increased Flu Activity; Real-World Data for Drug Safety, Efficacy
January 30, 2019 – AJMC Staff
Senate Committee Discusses the Burden of High Drug Prices and Potential Solutions
January 30, 2019 – Laura Joszt
Medicare Patients With Type 2 Diabetes Safely Switched From Analog to Human Insulin, JAMA Study Finds
January 29, 2019 – Mary Caffrey
FDA Approves Ibrutinib Combination as Frontline Treatment for CLL
January 28, 2019 – Jaime Rosenberg
AJMC® in the Press, January 25, 2019
January 25, 2019 – AJMC Staff
What We're Reading: Insulin Costs Double; PhRMA's Record Spending; Causes of Liver Transplants
January 23, 2019 – AJMC Staff

What We're Reading: Dietary Supplement Action; AI in Healthcare; Border Crossings for Medicine

AJMC Staff
An FDA announcement that it would step up oversight of the $50-billion-a-year dietary supplements industry was met with mixed reaction; a group of researchers in the United States and China are testing artificial intelligence (AI) to automatically diagnose common childhood conditions after processing data; close to 1 million people in California alone cross the border to Mexico annually for healthcare, including to buy prescription drugs.

Reaction to FDA Dietary Supplement Move Mixed

An FDA announcement that it would step up oversight of the $50-billion-a-year dietary supplements industry was met with mixed reaction, The Washington Post reported.  Some said the move is little more than a public relations effort, while others welcomed the effort to crack down on companies making false and misleading claims about health benefits or selling products adulterated with unlisted drug ingredients.

 

US, Chinese Researchers Working on AI Diagnostic System

A group of researchers in the United States and China are testing artificial intelligence (AI) to automatically diagnose common childhood conditions after processing the patient’s symptoms, history, lab results, and other clinical data, The New York Times reported. The AI system was highly accurate, according to findings. The report noted that the effort was aided by the fact that China’s privacy norms put fewer restrictions on the sharing of digital data drawn from a large Chinese population.

 

Californians Cross the Border to Mexico for Cheaper Prescription Drugs

Close to 1 million people in California alone cross the border to Mexico annually for healthcare, including to buy prescription drugs, Kaiser Health News reported. In Mexico, one type of insulin costs $600 for a 3-month supply compared with the $3700 price tag in the United States. The FDA largely looks the other way for people traveling and bringing medications back, as long as it is no more than a 90-day supply, but that could change at any time, experts said.

Related Articles

Utilizing Artificial Intelligence to Advance Care and Make Meaning of Data
Congress' Diabetes Caucus Seeks Transparency, Value-Based Contracts to Control Insulin Prices
What We're Reading: Pharma to Testify at Drug Pricing Hearing; Netflix Model for Hep C Drug; Marijuana and Other Drugs
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up